⌘K
t
Polarean Imaging Plc noted TR-1 announcements on 12 January 2024, detailing the sale of 9.5 million Polarean shares. Amati Global Investors Ltd sold these shares to NUKEM Isotopes GmbH. Following this transaction, NUKEM Isotopes GmbH's holding in Polarean increased to 10.458%.
| Date | 15 Jan 2024 |
| Time | 07:00:03 |
| Category | Miscellaneous |
| ID | 6114Z |
Polarean Imaging Plc
("Polarean" or the "Company")
Comment re: share purchase
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging ("MRI") of the lungs, notes the TR-1 announcements released on 12 January 2024 showing the sale of 9.5 million Polarean shares held by Amati Global Investors Ltd to NUKEM Isotopes GmbH ("NUKEM Isotopes"), a strategic partner and investor in the Company. This transaction highlights the significant support NUKEM Isotopes has in Polarean, and has increased NUKEM Isotopes's Polarean holding to 10.458%.
NUKEM Isotopes GmbH is a leading trading company for stable isotopes used in different fields for various applications. They have established reliable partnerships with gas manufacturers for the production of highly pure noble gases. The company is located in Alzenau, Germany.
Enquiries:
|
Polarean Imaging plc |
www.polarean.com / www.polarean-ir.com |
|||||
|
Christopher von Jako, Ph.D, Chief Executive Officer |
Via Walbrook PR |
|||||
|
Charles Osborne, Chief Financial Officer |
|
|||||
|
|
|
|||||
|
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) |
+44 (0)20 7710 7600 |
|||||
|
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) |
|
|||||
|
Nick Adams / Nick Harland (Corporate Broking) |
|
|||||
|
|
|
|||||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
|||||
|
Anna Dunphy / Phillip Marriage |
Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082 |
|||||
About Polarean (www.polarean.com)
The Company and its wholly-owned U.S. subsidiary, Polarean, Inc. are revenue-generating, medical imaging technology companies. The Company aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community which is desperately in need of new modern solutions to evaluate lung function. Polarean is dedicated to researching, developing, and commercialising these novel imaging solutions with their non-invasive and radiation-free functional MRI platform. The Company strives to address the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI contrast agent (XENOVIEW™) to be FDA-approved in the United States. The Company also commercialises the systems, software, and accessories to support fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
PLC-RNS-2326